E-钙黏蛋白和 syndecan-1 在接受放化疗的晚期非小细胞肺癌患者中的表达。
E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy.
机构信息
Department of Radiation Oncology, Norfolk and Norwich University Hospital, Norwich, U.K.
Department of Radiation Oncology, University Hospital of Ioannina, Ioannina, Greece.
出版信息
In Vivo. 2020 Jan-Feb;34(1):453-459. doi: 10.21873/invivo.11795.
BACKGROUND/AIM: The aim of the study was to investigate whether E-cadherin and syndecan-1 are molecular markers of advanced non-small cell lung cancer (NSCLC).
PATIENTS AND METHODS
The expression of E-cadherin and syndecan-1 (SDC1) was examined immunohistochemically on tissue specimens of 64 patients, with stage III disease at presentation. The obtained expression data were correlated with clinical parameters.
RESULTS
Negative expression of SDC1 was correlated with squamous histology (p=0.002). E-cadherin positive expression was significantly associated with increased 2-year overall survival (OS) rate (p=0.032). In the multivariate Cox analysis, performance status 0-1 was an independent predictor of OS (p=0.001) and disease-free survival (DFS) (p=0.001). E-cadherin expression was an independent predictor of OS (p=0.007) and DFS (p=0.029).
CONCLUSION
E-cadherin might be a prognostic factor for OS and DFS in advanced stage NSCLC patients. Further investigations are needed for the establishment of E-cadherin and syndecan-1 as molecular markers, affecting treatment response and survival.
背景/目的：本研究旨在探讨 E-钙黏蛋白和 syndecan-1 是否为晚期非小细胞肺癌（NSCLC）的分子标志物。
患者与方法
对 64 例初诊为 III 期疾病的患者的组织标本进行了 E-钙黏蛋白和 syndecan-1（SDC1）的免疫组织化学表达检测。所得表达数据与临床参数相关联。
结果
SDC1 的阴性表达与鳞状组织学相关（p=0.002）。E-钙黏蛋白阳性表达与 2 年总生存率（OS）的提高显著相关（p=0.032）。在多变量 Cox 分析中，体能状态 0-1 是 OS（p=0.001）和无病生存期（DFS）（p=0.001）的独立预测因素。E-钙黏蛋白表达是 OS（p=0.007）和 DFS（p=0.029）的独立预测因素。
结论
E-钙黏蛋白可能是晚期 NSCLC 患者 OS 和 DFS 的预后因素。需要进一步研究以确立 E-钙黏蛋白和 syndecan-1 作为影响治疗反应和生存的分子标志物。
Zotero 插件